Dr.Reddy's Laboratories Ltd (REDY.BO)
|Market Cap (Mil.):||Rs506,883.00|
|Shares Outstanding (Mil.):||170.34|
Reuters Market Eye - Shares in Dr.Reddy's Laboratories gain 1.58 percent vs a 0.02 percent fall in the Nifty.
* Shares in India's Dr.Reddy's Laboratories gain 1.1 percent vs a 0.2 percent fall in the NSE index. * A filing with the U.S. Securities and Exchange Commission on Monday shows market share gains in key drugs in the U.S. market, analysts say. (http://1.usa.gov/1tk9u78) (email@example.com / firstname.lastname@example.org)
* India's Dr.Reddy's Laboratories Ltd April-June operating profit may lag consensus, Thomson Reuters StarMine's SmartEstimates shows. * Dr.Reddy's may report operating profit of 7.42 billion rupees ($123.3 million) as per SmartEstimates, versus the consensus mean of 7.70 billion rupees. * Dr.Reddy's reports results later in the day. * Shares up 0.3 percent as of 0500 GMT. ($1 = 60.1700 Indian Rupees) (email@example.com / firstname.lastname@example.org)
Reuters Market Eye - Shares of Dr. Reddy's Laboratories rise, adding to Friday's 1.8 percent gain, after the drugmaker's annual report last week provided key details about spending on building capacity, raising hopes that expenses would reduce after FY16, dealers say.
* Shares of India's Dr. Reddy's Laboratories up 1 percent, adding to Friday's 1.8 percent gain, after the drugmaker's annual report last week provided key details about spending on building capacity, raising hopes that expenses would reduce after FY16, dealers say. * Dr. Reddy's said in its annual report filed with the U.S. Securities and Exchange Commission that the company would finance expansion plans through operating cash flow and through cash and other investments, and that the majority of
* Shares in Indian drugmakers fall, with Dr Reddy's Laboratories down 1.9 percent, on concerns that sales in Russia and Ukraine will be hit given military tensions between the two countries. * Dr. Reddy's has the highest exposure to Russia and former Soviet republics, with the region comprising 14.5 percent of sales, Bank of America-Merrill Lynch says in a note dated on Monday. * Ranbaxy Laboratories Ltd and Glenmark Pharmaceuticals Ltd also have exposure to Russia and former Soviet republics,